Metabolic Changes as a Diagnostic Indicator for Cancer
1 other identifier
observational
426
1 country
2
Brief Summary
This study aims to determine whether metabolic changes occur in blood plasma of cancer patients, and whether these changes can be used as a biomarker to detect cancer. These analyses will be done by means of nuclear magnetic resonance (NMR) spectroscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2009
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2012
CompletedFirst Submitted
Initial submission to the registry
December 10, 2013
CompletedFirst Posted
Study publicly available on registry
February 13, 2015
CompletedFebruary 13, 2015
February 1, 2015
2.8 years
December 10, 2013
February 9, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Metabolic phenotype of cancer
Significant metabolic changes in blood between cancer patients \& control subjects
day 1
Study Arms (3)
breast cancer patients
lung cancer patients
control subjects
Interventions
Collection of a venous blood sample to investigate metabolic changes in blood
Eligibility Criteria
Diagnosis of breast or lung cancer
You may qualify if:
- Diagnosis of breast or lung cancer (new lesion)
You may not qualify if:
- Not fasted for at least 6 hours
- Plasma glucose concentration ≥ 200 mg/dl
- Intake of medication at the day of investigation
- History/treatment of cancer in the previous 5 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hasselt Universitylead
- Ziekenhuis Oost-Limburgcollaborator
- Algemeen Ziekenhuis Vesaliuscollaborator
- Ziekenhuis Maas en Kempencollaborator
- Mariaziekenhuis Noord-Limburgcollaborator
Study Sites (2)
Ziekenhuis Oost-Limburg
Genk, Limburg, 3600, Belgium
Hasselt University
Hasselt, Limburg, 3500, Belgium
Related Publications (1)
Louis E, Adriaensens P, Guedens W, Vanhove K, Vandeurzen K, Darquennes K, Vansteenkiste J, Dooms C, de Jonge E, Thomeer M, Mesotten L. Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types? Ann Oncol. 2016 Jan;27(1):178-84. doi: 10.1093/annonc/mdv499. Epub 2015 Oct 20.
PMID: 26487580DERIVED
Biospecimen
Metabolic phenotype of cancer
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michiel Thomeer, prof. dr.
Ziekenhuis Oost-Limburg
- PRINCIPAL INVESTIGATOR
Kurt Baeten, dr.
Hasselt University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- prof. dr.
Study Record Dates
First Submitted
December 10, 2013
First Posted
February 13, 2015
Study Start
October 1, 2009
Primary Completion
July 1, 2012
Study Completion
July 1, 2012
Last Updated
February 13, 2015
Record last verified: 2015-02